0001140361-16-053976.txt : 20160218 0001140361-16-053976.hdr.sgml : 20160218 20160218174557 ACCESSION NUMBER: 0001140361-16-053976 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160216 FILED AS OF DATE: 20160218 DATE AS OF CHANGE: 20160218 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9143477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanofi CENTRAL INDEX KEY: 0001121404 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 161439193 BUSINESS ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 BUSINESS PHONE: 33153774400 MAIL ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 FORMER NAME: FORMER CONFORMED NAME: SANOFI-AVENTIS DATE OF NAME CHANGE: 20040826 FORMER NAME: FORMER CONFORMED NAME: SANOFI SYNTHELABO SA DATE OF NAME CHANGE: 20010104 4 1 form4.xml REGENERON PHARMACEUTICALS, INC FORM 4 2-16-2016 (SANOFI) X0306 4 2016-02-16 0000872589 REGENERON PHARMACEUTICALS INC REGN 0001121404 Sanofi 54 RUE LA BOETIE PARIS I0 75008 FRANCE true Common Stock 2016-02-16 4 P 0 2145 387.4283 A 23194653 I See note Common Stock 2016-02-16 4 P 0 2196 388.2999 A 23196849 I See note Common Stock 2016-02-16 4 P 0 6789 389.4759 A 23203638 I See note Common Stock 2016-02-16 4 P 0 14303 390.4695 A 23217941 I See note Common Stock 2016-02-16 4 P 0 33131 391.3591 A 23251072 I See note Common Stock 2016-02-16 4 P 0 14692 392.3656 A 23265764 I See note Common Stock 2016-02-16 4 P 0 7301 393.2723 A 23273065 I See note Common Stock 2016-02-16 4 P 0 600 393.95 A 23273665 I See note Common Stock 2016-02-17 4 P 0 1507 390.1449 A 23275172 I See note Common Stock 2016-02-17 4 P 0 3681 391.2307 A 23278853 I See note Common Stock 2016-02-17 4 P 0 27088 391.8482 A 23305941 I See note Common Stock 2016-02-17 4 P 0 6730 393.1577 A 23312671 I See note Common Stock 2016-02-17 4 P 0 12988 394.2403 A 23325659 I See note Common Stock 2016-02-17 4 P 0 13288 395.3203 A 23338947 I See note Common Stock 2016-02-17 4 P 0 11018 396.2026 A 23349965 I See note Common Stock 2016-02-17 4 P 0 3400 397.0707 A 23353365 I See note Common Stock 2016-02-17 4 P 0 300 398.38 A 23353665 I See note The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). Purchase prices range from $386.74 to $387.60 per share, inclusive. Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,554,113 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Purchase prices range from $387.82 to $388.73 per share, inclusive. Purchase prices range from $388.91 to $389.90 per share, inclusive. Purchase prices range from $389.95 to $390.93 per share, inclusive. Purchase prices range from $390.95 to $391.93 per share, inclusive. Purchase prices range from $391.95 to $392.94 per share, inclusive. Purchase prices range from $392.95 to $393.87 per share, inclusive. Purchase price was $393.95 per share. Purchase prices range from $389.68 to $390.52 per share, inclusive. Purchase prices range from $390.70 to $391.69 per share, inclusive. Purchase prices range from $391.73 to $392.71 per share, inclusive. Purchase prices range from $392.73 to $393.66 per share, inclusive. Purchase prices range from $393.74 to $394.72 per share, inclusive. Purchase prices range from $394.74 to $395.73 per share, inclusive. Purchase prices range from $395.75 to $396.74 per share, inclusive. Purchase prices range from $396.81 to $397.68 per share, inclusive. Purchase price was $398.38 per share. /s/ Alexandra Roger, Head of Securities Law and Capital Markets 2016-02-18